IRIS

Response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C due to genotype 4.

BRUNO, RAFFAELE;
2008-01-01
2008
The Clinical Immunology & Infectious Diseases category covers resources that focus on basic research in clinical and applied allergy, immunology, and infectious disease. Microbiology and virology resources are included in this category as are resources on HIV, AIDS, sexually transmitted diseases (STDs), and hospital infections.
JOURNAL OF VIRAL HEPATITIS
sì
000259350000002
Sì, ma tipo non specificato
Inglese
Internazionale
STAMPA
15
710
715
5
18637070
SUMMARY: Hepatitis C virus (HCV) genotypes 1 and 4 respond less well to pegylated interferon (pegIFN) plus ribavirin (RBV) therapy. For this reason most studies merge these two genotypes when assessing virological response. However, in most trials the HCV genotype 4 population is rather small, and conclusions are mainly derived from what occurs in HCV-1 patients. All HCV-4 patients coinfected with HIV who received pegIFN plus RBV in two different multicentre studies, PRESCO and ROMANCE, conducted respectively in Spain and Italy, were retrospectively analyzed. Baseline plasma HCV-RNA, proportion of patients with HCV-RNA <10 IU / mL at week 4 (rapid virological response), and HCV-RNA declines >2 logs at week 12 (early virological response, EVR) were all assessed as predictors of sustained virological response (SVR). Overall, 75 patients (60 men) were evaluated. Median age was 40 years and median CD4 count 598 cells / mm(3); 49\% had plasma HIV-RNA <50 copies / mL; 71\% had elevated liver enzymes and 31\% had advanced liver fibrosis (Metavir F3-F4). Median serum HCV-RNA was 5.7 log IU / mL. Rapid virological response was attained by 10 (20\%) patients and EVR by 26 (42\%). Using intention-to-treat and on-treatment (OT) analyses, SVR was achieved by 21 / 75 (28\%) and 21 / 62 (34\%) of HCV-4 patients, respectively. In the multivariate analysis (OT), baseline HCV-RNA (OR 0.09 for every log increment; 95\% CI: 0.01-0.7) and EVR (OR: 7.08; 95\% CI: 1.8-27.2) were significantly and independently associated with SVR. This is the largest series of HIV-infected patients with chronic hepatitis C due to HCV-4 treated with pegIFN plus RBV examined so far and the results show that HCV-4 behaves similarly to HCV-1. Therefore, these patients should be considered as difficult to treat population. Baseline serum HCV-RNA and EVR are the best predictors of SVR in HCV-4 / HIV-coinfected patients.
HCV; Viral hepatitis; interferon therapy
11
info:eu-repo/semantics/article
262
L., Martín Carbonero; M., Puoti; J., García Samaniego; A., De Luca; E., Losada; G., Quinzan; Bruno, Raffaele; A., Mariño; M., González; M., Núñez; V.,...espandi
1 Contributo su Rivista::1.1 Articolo in rivista
none
1.1 Articolo in rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11571/148762
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 16
social impact